K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action via antioxidative pathway activation

PLoS One. 2013 Sep 11;8(9):e75189. doi: 10.1371/journal.pone.0075189. eCollection 2013.

Abstract

Pharmacological modulation of ATP-sensitive potassium channels has become a promising new therapeutic approach for the treatment of neurodegenerative diseases due to their role in mitochondrial and cellular protection. For instance, diazoxide, a well-known ATP-sensitive potassium channel activator with high affinity for mitochondrial component of the channel has been proved to be effective in animal models for different diseases such as Alzheimer's disease, stroke or multiple sclerosis. Here, we analyzed the ability of diazoxide for protecting neurons front different neurotoxic insults in vitro and ex vivo. Results showed that diazoxide effectively protects NSC-34 motoneurons from glutamatergic, oxidative and inflammatory damage. Moreover, diazoxide decreased neuronal death in organotypic hippocampal slice cultures after exicitotoxicity and preserved myelin sheath in organotypic cerebellar cultures exposed to pro-inflammatory demyelinating damage. In addition, we demonstrated that one of the mechanisms of actions implied in the neuroprotective role of diazoxide is mediated by the activation of Nrf2 expression and nuclear translocation. Nrf2 expression was increased in NSC-34 neurons in vitro as well as in the spinal cord of experimental autoimmune encephalomyelitis animals orally administered with diazoxide. Thus, diazoxide is a neuroprotective agent against oxidative stress-induced damage and cellular dysfunction that can be beneficial for diseases such as multiple sclerosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / metabolism*
  • Cell Line
  • Cell Survival / drug effects
  • Cerebellum / cytology
  • Diazoxide / pharmacology*
  • Dose-Response Relationship, Drug
  • Encephalomyelitis, Autoimmune, Experimental / pathology
  • Female
  • Hippocampus / cytology
  • Ion Channel Gating / drug effects*
  • KATP Channels / metabolism*
  • Mice
  • Microglia / cytology
  • Microglia / drug effects
  • Microglia / metabolism
  • Motor Neurons / cytology
  • Motor Neurons / drug effects
  • Motor Neurons / metabolism
  • Myelin Sheath / drug effects
  • Myelin Sheath / physiology
  • NF-E2-Related Factor 2 / metabolism
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / pathology
  • Neurodegenerative Diseases / prevention & control*
  • Neuroprotective Agents / pharmacology*
  • Neurotoxins / toxicity
  • Oxidative Stress / drug effects
  • Protein Transport / drug effects
  • Rats
  • Spinal Cord / pathology

Substances

  • Antioxidants
  • KATP Channels
  • NF-E2-Related Factor 2
  • Neuroprotective Agents
  • Neurotoxins
  • Nfe2l2 protein, mouse
  • Diazoxide

Grants and funding

The study was supported by by Ministerio de Economia y Competividad (INNPACTO Program) and by l’Agència de Suport a l’Empresa Catalana (ACC1Ó) (Nuclis d’Innovació Tecnològica program), Generalitat de Catalunya, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.